<DOC>
	<DOC>NCT03019887</DOC>
	<brief_summary>To reduce antipsychotics to under 1000mg in patients with schizophrenia taking more than 1000mg/day and to evaluate relationship between relapse and cognitive function.</brief_summary>
	<brief_title>Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction of High-dose Antipsychotic Therapy</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Perphenazine</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Methotrimeprazine</mesh_term>
	<criteria>inpatients with a diagnosis of schizophrenial, and those in the chronic phase receiving mean daily antipsychotic doses exceeding 1000mg CPZ eq./day. mental retardation, substance abuse or dependence, a history of major head trauma, serious medical or neurological disorders, or depot antipsychotic injections within the previous 3 months and electroconvulsive therapy within the previous 6 months</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>